Madrigal Pharmaceuticals (MDGL) Non-Current Assets (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Non-Current Assets data on file, last reported at $45.0 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 420.46% year-over-year to $45.0 million in Q1 2026; TTM through Mar 2026 was $86.6 million, a 143.17% increase from a year earlier, with the FY2025 full-year figure at $13.8 million, up 48.27% from the prior year.
• Non-Current Assets for Q1 2026 stood at $45.0 million, up from $13.8 million in the prior quarter.
• Over the last five years, Non-Current Assets for MDGL reached as high as $45.0 million in Q1 2026 and fell as low as $866000.0 in Q2 2023.
• Historically, Non-Current Assets has averaged $8.5 million across 5 years, with a median of $8.1 million in 2024.
• Across the five-year window, Non-Current Assets sank 53.09% in 2023 and jumped 830.83% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $1.2 million in 2022, then jumped by 171.49% to $3.3 million in 2023, then surged by 185.36% to $9.3 million in 2024, then surged by 48.27% to $13.8 million in 2025, then soared by 225.78% to $45.0 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $45.0 million in Q1 2026, $13.8 million in Q4 2025, and $15.8 million in Q3 2025.